Latest News

If you are wondering whether Primo Brands at around $15.77 is a bargain or a value trap, you are not alone. This stock has all the ingredients of a classic valuation puzzle. Over the last month the share price has climbed roughly 9.1%, even though it is still down 49.1% year to date and 47.7% over the last year. This suggests that sentiment is shifting, but the long-term scars are still visible. That recent rebound has come as investors digested a series of strategic updates, including...

If you have ever wondered whether Costco Wholesale is still a smart buy at around $887 a share, you are not alone. Plenty of investors are trying to figure out if the current price still leaves room for value. The stock has slipped recently, down about 2.7% over the last week, 3.8% over the past month, and 2.5% year to date, yet it still sits on gains of 89.6% over 3 years and 150.5% over 5 years, which keeps the long term story in focus. Much of the recent share price action has been driven...

Wondering if Crown Holdings is actually good value at around $94 a share, or if the easy money has already been made, you are not alone. Despite being up 16.0% year to date and 8.5% over the last year, the stock has cooled recently with a 4.0% dip over the past week and a 3.7% slide across the last month. Those moves have come as investors reassess packaging stocks more broadly, with Crown often in the conversation thanks to its global footprint and exposure to consumer staples. At the same...

Advanced Micro Devices (AMD) stock is back in the spotlight after President Donald Trump moved to let US chipmakers resume selling advanced AI processors to approved customers in China, subject to new oversight and a 25% fee. See our latest analysis for Advanced Micro Devices. The policy shift arrives while AMD is already riding a powerful AI wave, with a 90 day share price return of 38.91% and a 1 year total shareholder return of 73.49%, signaling momentum that investors clearly still buy...

In recent days, VanEck’s Matthew Sigel highlighted that MARA Holdings’ US$3.30 billion in convertible debt and structurally high short interest mean its valuation is heavily shaped by its balance sheet rather than simple bitcoin exposure. At the same time, a very large 43,033 BTC transfer to Jack Mallers’ Twenty One ahead of its NYSE listing has put fresh attention on where MARA sits among the largest corporate bitcoin holders and how its financing choices influence its risk...

With its stock down 17% over the past three months, it is easy to disregard Ajinomoto (TSE:2802). However, stock prices...

If you are wondering whether JD.com is quietly turning into a value opportunity after years of pain, you are not alone. This is exactly the question we are going to unpack. Despite a tough run, with the share price down about 1.2% over the last week, 6.6% over the past month, and still roughly 22.8% lower over the last year, the stock is starting to look more interesting to value focused investors. Recent headlines have focused on JD.com sharpening its focus on core e commerce, doubling down...

Wondering if Novo Nordisk is still worth buying after all the excitement around weight loss and diabetes treatments, or if the best days are already priced in. The stock has been choppy recently, down 2.6% over the last week but still up 2.7% over the past month, and longer term it has swung from a 53.8% gain over five years to a steep 60.7% drop in the last year, which says a lot about shifting expectations and risk appetite. Those moves sit against a backdrop of ongoing buzz around its GLP...

Wondering if United Airlines Holdings is still good value after its big run, or if most of the upside has already been priced in? You are not alone. That is exactly what this piece will unpack. United's share price has climbed 3.3% over the last week, 7.3% over the past month, and is up 9.5% year to date, adding to a hefty 136.2% gain over three years and 123.7% over five years that has reshaped how investors see its risk and reward profile. Those moves have come as investors react to a mix...

Vulcan Materials (VMC) has been quietly grinding higher this year, and its recent price action is giving investors a chance to reassess what they are really paying for its steady infrastructure exposure. See our latest analysis for Vulcan Materials. The 13.88% year to date share price return suggests momentum is still broadly constructive. However, the recent pullback toward 291.04 hints at investors periodically reassessing infrastructure demand and what they are willing to pay for Vulcan’s...

Key Insights China Communications Construction's significant private companies ownership suggests that the key...

CleanSpark, Inc. has already reported unaudited October 2025 production of 587 Bitcoin and fiscal 2025 results showing revenue of US$766.31 million and net income of US$364.46 million, marking a major turnaround from the prior year's loss. Alongside record profitability, the company is expanding into AI and high-performance computing while holding 13,054 Bitcoin and funding growth through US$1.15 billions in zero-coupon convertible notes and large-scale share repurchases. We’ll now examine...

AutoZone (AZO) opened fiscal Q1 2026 with total revenue of $4.6 billion and basic EPS of $31.88, setting the stage against a backdrop where trailing twelve month revenue sits at $19.3 billion and EPS at $147.34. Over recent quarters the company has seen revenue move from $6.2 billion in Q4 2024 to $6.2 billion in Q4 2025 and then to $4.6 billion in Q1 2026, while quarterly EPS tracked from $53.0 to $50.0 and now $31.9, leaving investors weighing solid top line scale against signs of...

Omnicell recently launched Omnicell Titan XT in the United States, an enterprise-grade automated dispensing system powered by its cloud-based, HITRUST-certified OmniSphere platform to unify medication management across health systems. The system’s AI-enabled inventory intelligence and embedded FiveRights safety safeguards position Titan XT as a platform play aimed at reducing medication errors and optimizing pharmacy and nursing workflows across entire hospital networks. Next, we’ll examine...

Most readers would already be aware that China National Culture Group's (HKG:745) stock increased significantly by 24...

In November 2025, FluoGuide A/S announced a non-exclusive collaboration agreement with ZEISS Medical Technologies to advance FG001 for tumor imaging and surgical margin assessment in head and neck cancer, focused on supporting the clinical phase and with no initial payment or expected financial impact in 2025. This partnership underlines Carl Zeiss Meditec’s continued push into precision oncology imaging, where integrating advanced optics with novel tracers could broaden its long-term...

Wondering if Blue Owl Capital is a bargain or a value trap at around $16 a share? You are not alone, and this is exactly the kind of stock where a closer look at valuation can really pay off. The share price has bounced about 6.6% over the last week and 3.8% over the past month, but that still sits against a much tougher backdrop with the stock down 32.1% year to date and 28.3% over the last year. Even so, the 3 year and 5 year returns are 59.3% and 86.7% respectively. Some of this recent...

Flowers Foods (FLO) has been sliding this year, and that weak share performance is exactly why the stock is getting fresh attention from value focused investors looking for a reset. See our latest analysis for Flowers Foods. That drop has left the share price at about $10.71, and with a roughly 48% year to date share price return decline and a similar slide in the one year total shareholder return, momentum clearly looks to be fading rather than stabilising. If Flowers Foods' slump has you...

If you are wondering whether PTC is quietly becoming a bargain or if the market is rightly cautious at today’s price, you are in the right place to unpack what the numbers are really saying about its value. Despite a solid 40.6% gain over three years and 53.2% over five years, the stock is down 12.6% over the last year and 4.7% year to date, suggesting sentiment has cooled even as the longer term picture still looks constructive. Recent headlines have focused on PTC’s continued push in...

NorthWest Healthcare Properties Real Estate Investment Trust (TSX:NWH.UN) is back in the spotlight after returning to profitability in Q3 2025, helped by a 4% same property NOI lift and tighter cost control. See our latest analysis for NorthWest Healthcare Properties Real Estate Investment Trust. The latest turnaround has not sparked fireworks in the share price yet, with a roughly 17% year to date share price return and a still deeply negative three year total shareholder return. This...

IREN (NasdaqGS:IREN) just pushed through a multi billion dollar mix of convertible notes and new equity, a move that hit the stock but is central to funding its AI and data center pivot. See our latest analysis for IREN. Those hefty offerings landed on a stock that has already been on a wild ride, with a 30 day share price return of minus 25.71% but a 90 day share price return of 53.49%, and a three year total shareholder return above 3,100%. This suggests long term momentum is still very...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

What underlying fundamental trends can indicate that a company might be in decline? When we see a declining return on...